(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Homocystinuria- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Homocystinuria pipeline landscape is provided which includes the disease overview and Homocystinuria treatment guidelines. The assessment part of the report embraces, in depth Homocystinuria commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Homocystinuria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Homocystinuria R&D. The therapies under development are focused on novel approaches to treat/improve Homocystinuria.
Homocystinuria Emerging Drugs Chapters
This segment of the Homocystinuria report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Homocystinuria Emerging Drugs
TVT-058: Travere Therapeutics
Pegtibatinase (TVT-058) is an investigational PEGylated, recombinant enzyme replacement therapy designed to address the underlying cause of classical homocystinuria (HCU). In preclinical studies, pegtibatinase has demonstrated an ability to reduce total homocysteine levels and improve clinical parameters. Pegtibatinase is currently advancing in the Phase III Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. Pegtibatinase has been granted Rare Pediatric Disease and Fast Track designations by the US Food and Drug Administration (FDA), as well as Orphan Drug designation in the US and Europe.
Homocystinuria: Therapeutic Assessment
Homocystinuria: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Homocystinuria therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Homocystinuria drugs.
Major Players in Homocystinuria
There are approx. 3+ key companies which are developing the therapies for Homocystinuria. The companies which have their Homocystinuria drug candidates in the most advanced stage, i.e. Phase III include, Travere Therapeutics.
Key Questions
How many companies are developing Homocystinuria drugs? How many Homocystinuria drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Homocystinuria? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Homocystinuria therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Homocystinuria and their status? What are the key designations that have been granted to the emerging drugs?
Key Players
Travere Therapeutics Syntis Bio
Key Products
Phases
Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates
Route of Administration
Oral Intravenous Subcutaneous Parenteral Topical Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type
Homocystinuria Report Insights
Homocystinuria Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs
Homocystinuria Report Assessment
Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs
For more information about this drug pipelines report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN18122024004107003653ID1109007732
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.